Autopsy report · NCT05271279

A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors

“Research and development strategy adjustment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 8 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

Beijing Boren Hospital

Sponsor type

University, hospital or other

Conditions

Advanced Solid Tumor; Relapsed/Refractory Lymphoma

Interventions

OVV-01 Injection+IBR900 Cell Injection

Participants

2

Sites

1

Countries

China

Trials that died the same way

• A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
  “company development strategy adjustment” (80% match in meaning)
• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (74% match in meaning)
• IBI397 or Combination Therapies in Patients With Advanced Malignancies
  “Due to the company's development strategy adjustment” (71% match in meaning)
• A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
  “Alternate development strategy” (71% match in meaning)
• Study of NIB101 in Participants With Advanced Solid Tumors
  “due to the reconsideration of development strategy” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.